Stock Events

Stock Events

Tvardi Therapeutics 

$3.04
0
+$0.09+3.05% Wednesday 04:00

Statistics

Day High
3.06
Day Low
3.04
52W High
-
52W Low
-
Volume
460
Avg. Volume
-
Mkt Cap
28.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-1
-0.86
-0.73
-0.59
Expected EPS
-0.744286
Actual EPS
N/A

Financials

-992.95%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
14.27MRevenue
-141.73MNet Income

Analyst Ratings

3Average Price Target
The highest estimate is 3.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
50%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TVRD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals is involved in creating treatments for pain management, directly competing with Cara Therapeutics' focus on novel pain therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.65B
Teva Pharmaceutical Industries has a broad portfolio that includes pain management solutions, making it a competitor in the same therapeutic area as Cara Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap564.35B
Johnson & Johnson, through its pharmaceutical segment, develops drugs for various conditions including pain, competing with Cara Therapeutics' pain management products.
Abbvie
ABBV
Mkt Cap368.57B
AbbVie has a strong presence in the pain management market with its portfolio of analgesics, competing with Cara Therapeutics.
Pfizer
PFE
Mkt Cap156.77B
Pfizer has a diverse drug portfolio that includes pain management medications, positioning it as a competitor to Cara Therapeutics.
Novartis
NVS
Mkt Cap293.34B
Novartis AG offers a range of pain management solutions, making it a direct competitor in the therapeutic area that Cara Therapeutics targets.
Merck
MRK
Mkt Cap294.39B
Merck & Co., Inc. develops medications for various therapeutic areas, including pain, competing with Cara Therapeutics' focus.
Gilead Sciences
GILD
Mkt Cap170.84B
Gilead Sciences, though primarily known for antiviral drugs, has ventured into other therapeutic areas, including pain management, competing with Cara Therapeutics.
Alkermes
ALKS
Mkt Cap5.56B
Alkermes plc works on central nervous system (CNS) disorders, including treatments for pain, positioning it as a competitor to Cara Therapeutics.

About

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Show more...
CEO
ISIN
US1407553072

Listings

XNAS
US
TVRD
LSE
GB
0HTC.LSE
MU
DE
69C.MU
F
DE
69C.F

0 Comments

Share your thoughts

FAQ

What is Tvardi Therapeutics stock price today?▼
The current price of TVRD.BOATS is $3.04 USD — it has increased by +3.05% in the past 24 hours. Watch Tvardi Therapeutics stock price performance more closely on the chart.
What is Tvardi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tvardi Therapeutics stocks are traded under the ticker TVRD.BOATS.
What is Tvardi Therapeutics market cap?▼
Today Tvardi Therapeutics has the market capitalization of 28.52M
When is the next Tvardi Therapeutics earnings date?▼
Tvardi Therapeutics is going to release the next earnings report on May 19, 2026.
What were Tvardi Therapeutics earnings last quarter?▼
TVRD.BOATS earnings for the last quarter are -0.78 USD per share, whereas the estimation was -0.65 USD resulting in a -20.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tvardi Therapeutics revenue for the last year?▼
Tvardi Therapeutics revenue for the last year amounts to 14.27M USD.
What is Tvardi Therapeutics net income for the last year?▼
TVRD.BOATS net income for the last year is -141.73M USD.
In which sector is Tvardi Therapeutics located?▼
Tvardi Therapeutics operates in the Other sector.
When did Tvardi Therapeutics complete a stock split?▼
Tvardi Therapeutics has not had any recent stock splits.